The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2025

Filed:

Jul. 31, 2017
Applicant:

Health Research, Inc., Buffalo, NY (US);

Inventors:

Kunle Odunsi, Williamsville, NY (US);

Richard Koya, Williamsville, NY (US);

Takemasa Tsuji, Williamsville, NY (US);

Assignee:

Health Research, Inc., Buffalo, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2005.12); A61K 35/17 (2014.12); A61K 39/00 (2005.12); C07K 14/725 (2005.12); C12N 5/0783 (2009.12); C12N 15/01 (2005.12); C12N 15/10 (2005.12); C12N 15/66 (2005.12); C12Q 1/6874 (2017.12); C12Q 1/6876 (2017.12); G01N 33/566 (2005.12); G01N 33/574 (2005.12);
U.S. Cl.
CPC ...
C12N 15/85 (2012.12); A61K 35/17 (2012.12); A61K 39/4611 (2023.04); A61K 39/4632 (2023.04); A61K 39/464488 (2023.04); C07K 14/7051 (2012.12); C12N 5/0638 (2012.12); C12N 15/01 (2012.12); C12N 15/1093 (2012.12); C12N 15/66 (2012.12); C12Q 1/6874 (2012.12); C12Q 1/6876 (2012.12); G01N 33/566 (2012.12); G01N 33/574 (2012.12); A61K 2239/31 (2023.04); A61K 2239/38 (2023.04); A61K 2239/59 (2023.04); C12N 2510/00 (2012.12);
Abstract

Provided are methods, compositions, recombinant DNA molecules, and kits for cloning T cell receptors (TCRs). The methods facilitate construction of TCR expression libraries from biological samples containing antigen-specific T cells, including but not limited to tumor biopsies, including frozen tumor biopsies. Peripheral T cells that were engineered with library-derived TCR genes show potent therapeutic anti-tumor effects. The method can be performed using any sample that contains T cells, and can be performed with oligoclonal populations of T cells, such as T cells that have infiltrated a tumor. Primer combinations for first strand cDNA synthesis, second strand cDNA synthesis, and for cloning a plurality of distinct TCR β and TCR α chains into a plurality of vectors are provided. Cells containing the vectors are provided, as are kits for use in rapid cloning of the TCR β and TCR α chains.


Find Patent Forward Citations

Loading…